|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
¿Ü±¹°èÁ¦¾àȸ»ç/Local Trial Manager(ÀÓ»ó)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
8³â¡è |
ä¿ë½Ã |
11.29 |
|
|
ÆÄÀε崺·ÎµåÄÁ¼³Æà |
¹Ì±¹°è ÈÀåǰȸ»ç RA Manager (Â÷-ºÎÀå±Þ)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
8³â¡è |
ä¿ë½Ã |
07.28 |
|
|
ÆÄÀε崺·ÎµåÄÁ¼³Æà |
±Û·Î¹ú Á¦¾à»ç/ RA Specialist (Á¤±ÔÁ÷/¾à»ç)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
06.26 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
À¯¸í ÄÚ½º´Ú »óÀå Á¦¾à»ç Ç°Áú°ü¸® ¾à»ç
Ãæ³² õ¾È½Ã, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.04 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
phamacovigilance Specialist
Ãæ³² õ¾È½Ã, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.04 |
|
|
¹Ý¼®½áÄ¡(ÁÖ) |
Áß°ßÁ¦¾à»ç / Á¦Á¦¿¬±¸ÆÀÀå
Ãæ³² ¾Æ»ê½Ã | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
10.18 |
|
|
JYpartners |
Pharmacist ÀǾàÇ° µµ¸Å ¹× ¹°·ù¼¾ÅÍ Ç°Áú°ü¸® (¾à»ç ÆÄÆ®
°æ±â ÆòÅýÃ, °æ±â ¿À»ê½Ã | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.24 |
|
|
¼¿ï¿Ü´ë½ºÄ«¿ìÆ® |
ÀǾàÇ° µµ¸Å Ç°Áú°ü¸® ¾à»ç´Ô
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.24 |
|
|
JYpartners |
[[¾à»ç, ÇѾà»ç Çʼö]] CRA 2³â ÀÌ»ó °æ·ÂÀÚ OK
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.06 |
|
|
Uway Consulting |
±¹³»¹ÙÀÌ¿À±â¾÷ ¾à»ç(Ç°Áú°ü¸®) ä¿ë
´ëÀü À¯¼º±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
05.06 |
|
|
¼¿ï¿Ü´ë½ºÄ«¿ìÆ® |
(¿Ü±¹°ÔÁ¦¾à»ç)PV 0-3°æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
03.11 |
|
|
JYpartners |
PD Product Manager
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Oncology´ã´ç °úÂ÷Àå±Þ)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
4³â¡è |
ä¿ë½Ã |
03.11 |
|
|
JYpartners |
[¿Ü±¹°è(µ¶ÀÏ)] Á¦¾àȸ»ç PM¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Team Manager/Èñ±ÍÁúȯFranchise(±¹³» »óÀ§±ÇÀÇ Á¦
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
7³â¡è |
ä¿ë½Ã |
01.13 |
|